Loading news...
SAN CARLOS, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the closing of its previously announced underwritten public offering of 12,650,000 shares of common stock at a public offering price of $50.00 per share.
SAN CARLOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the pricing of an underwritten public offering of common stock. Vaxcyte is selling 11,000,000 shares of common stock in the offering at a public offering price of $50.00 per share. The aggregate gross proceeds to Vaxcyte from this offering are expected to be $550 million, before deducting underwriting discounts and commissions and other offering expenses. All shares of common stock to be sold in the offering will be offered by Vaxcyte. Vaxcyte has granted the underwriters a 30-day option to purchase up to an additional 1,650,000 shares of its common stock at the public offering price per share, less underwriting discounts and commissions.
From a sector perspective, strength within Industrials and Information Technology offset relative weakness in Health Care. The October earnings report reinforced confidence in Comfort Systems' ability to convert a strong backlog and increasingly sophisticated project mix into sustained earnings growth. We did not make any adjustments to the position and continue to believe that the market opportunity remains robust.
SAN CARLOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that it has commenced an underwritten public offering of $500,000,000 of its common stock and pre-funded warrants.
VAX-31 Adult Indication: Vaxcyte Doses First Participants in Phase 3 Study Evaluating Concomitant Administration of VAX-31 and Seasonal Influenza Vaccine (OPUS-2) and Expects to Initiate Phase 3 Study in Adults Previously Vaccinated with Pneumococcal Vaccines (OPUS-3) in First Quarter of 2026
SG Americas Securities LLC increased its stake in Vaxcyte, Inc. (NASDAQ: PCVX) by 129.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 25,558 shares of the company's stock after acquiring an additional 14,421 shares during the period. SG
Vaxcyte, Inc. (NASDAQ: PCVX - Get Free Report) has earned an average recommendation of "Moderate Buy" from the ten ratings firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has issued
The CTO sold 9,743 shares. The sale represented 28.9% of Dhaliwal's holdings.
Vaxcyte, Inc. (NASDAQ: PCVX - Get Free Report) insider Harpreet Dhaliwal sold 9,743 shares of Vaxcyte stock in a transaction dated Wednesday, December 31st. The stock was sold at an average price of $46.69, for a total value of $454,900.67. Following the sale, the insider directly owned 23,928 shares in the company, valued at approximately $1,117,198.32.
Vaxcyte, Inc. (NASDAQ: PCVX - Get Free Report) SVP Elvia Cowan sold 11,623 shares of the firm's stock in a transaction dated Tuesday, December 23rd. The shares were sold at an average price of $47.92, for a total transaction of $556,974.16. Following the transaction, the senior vice president directly owned 14,534 shares in the company, valued
Vaxcyte keeps its place among Mizuho Securities top picks entering 2026.
Vaxcyte, Inc. (NASDAQ: PCVX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the ten brokerages that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, seven have given a buy recommendation and one has assigned a
Assenagon Asset Management S.A. raised its stake in Vaxcyte, Inc. (NASDAQ: PCVX) by 358.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 219,950 shares of the company's stock after acquiring an additional 171,974 shares during the period.
Vaxcyte is positioned to disrupt the pneumococcal vaccine market with its engineered VAX-31, overcoming carrier suppression limitations faced by incumbents. PCVX's $2.7B cash position supports an aggressive Phase 3 program, with a projected runway through 2028, mitigating financing and execution risks. VAX-31 targets 95% of U.S. adult IPD strains, aiming for best-in-class breadth and efficacy, with pivotal Phase 3 OPUS trial data expected in Q4 2026.
Trial Design Finalized in Consultation and Alignment with U.S. Food and Drug Administration Study Designed to Establish a New Standard for Adult Pneumococcal Conjugate Vaccines Through Head-to-Head Safety, Tolerability and Immunogenicity Comparisons of VAX-31 with Capvaxive (PCV21) and Prevnar 20 (PCV20), the Current Standards of Care Company Expects to Report Topline Safety, Tolerability and Immunogenicity Data for OPUS Phase 3, Noninferiority Trial in the Fourth Quarter of 2026 and Initiate Additional Phase 3 Studies in 2026 with Readouts in 2027, Supporting Planned BLA Submission VAX-31 is Designed to Cover ~95% of Invasive Pneumococcal Disease (IPD) and ~88% of Pneumococcal Pneumonia in U.S. Adults Aged 50+, with Potential to Provide an Incremental 14-34% Broader IPD Coverage and 19-31% Broader Pneumonia Coverage than Standard-of-Care Vaccines VAX-31 Aims to Advance Adult Pneumococcal Protection by Maintaining Critical Pressure on Both Currently Circulating and Long-Established, Historically Disease-Causing Serotypes, While Maintaining or Improving Immune Responses SAN CARLOS, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that the first participants were dosed in the OPUS (OPA-based Pivotal U.S. Study) Phase 3 pivotal, noninferiority trial evaluating VAX-31 for the prevention of invasive pneumococcal disease (IPD) and pneumonia in adults.
Edgestream Partners L.P. purchased a new position in shares of Vaxcyte, Inc. (NASDAQ: PCVX) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 49,518 shares of the company's stock, valued at approximately $1,610,000. Other hedge funds and other institutional investors have also recently bought
AXQ Capital LP acquired a new position in shares of Vaxcyte, Inc. (NASDAQ: PCVX) during the undefined quarter, according to its most recent 13F filing with the SEC. The fund acquired 8,754 shares of the company's stock, valued at approximately $285,000. Several other institutional investors and hedge funds also recently made changes to
Bank of Montreal Can boosted its stake in Vaxcyte, Inc. (NASDAQ: PCVX) by 4.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 31,547 shares of the company's stock after purchasing an additional 1,274 shares during the period. Bank of Montreal Can's
Final Data from VAX-24 Infant Phase 2 Dose-Finding Study Consistent with Previously Reported Positive Interim Data; Provide Additional Evidence Supporting Higher VAX-31 Doses Being Evaluated in Ongoing Infant Phase 2 Study